Vicore Pharma: Unlocking the potential of a new class of drugs, Angiotensin II type 2 receptor agonists, with disease-modifying potential in idiopathic pulmonary fibrosis (IPF)

Company in Brief

Vicore is an innovative clinical-stage pharmaceutical company with a vision to transform the lives of patients where modulation of the AT2 (angiotensin II type 2) receptor can play a central role in halting and reversing disease pathology.

Locations: Stockholm, Sweden, Cambridge, MA, USA & Copenhagen, Denmark

Employees: ~35 FTEs.

Ticker: VICO, listed at Nasdaq Stockholm

Website: www.vicorepharma.com

Management Team

Strong leadership team with extensive industry experience.

Ahmed Mousa* Chief Executive Officer	**Lene Eskildsen** Head of Quality Assurance	**Bertil Lindmark*** Chief Medical Officer
Johan Raud Chief Scientific Officer	**Johanna Gräns** Program Director, early development	**Bernt van den Blink*** VP Clinical Development
Nina Carlén Chief Administrative Officer	**Jonathan Langley** Head of Global Medical Affairs	**Anne-Katrine Cohrt** Head of Clinical Operations
Jimmie Hofman* VP Business Development	**Karin Eklund Vanderpol** Senior Director Regulatory Affairs	**Mikael Nygård** Chief Operating Officer
Hans Jeppsson Chief Financial Officer	**Helen Barker** VP and Head of CMC	**Megan Richards** VP Investor Relations, Communications and Portfolio Strategy

*Attending RIS

Board Members

Hans Schikan
25 years management experience in global pharmaceuticals (CEO of Prosensa & leading roles at Genzyme and Organon). Extensive board work in listed life science companies (Hansa Biopharma, Wilson Tx (acquired by Alexion), SOBI, Asceneuron, InteRNA and Therachon (acquired by Pfizer).

Jacob Gunterberg
Chairman. Former partner at HealthCap with extensive experience from venture capital investment operations and corporate finance in life science. Extensive experience as board member in both private and publicly traded companies.

Heidi Hunter
More than 25 years of experience from leading positions in different roles within pharmaceutical development and commercialization. Leadership experience spans alliance management, investment risk mitigation, global clinical and commercial management, new business strategy development, product launch, and business sustainability.

Ann Barbier
Ann has more than 20 years of drug discovery and development experience in the pharmaceutical and biotech worlds. She has contributed to several approved drugs and has worked in the rare disease, neuropsychiatry and pulmonology fields.

Elisabeth Björk
More than 15 years of experience from clinical practice, academic research and management of drug development in big pharma as well as global commercial strategy and implementation across regions and therapy areas. Currently leading global late-stage development activities in Cardiovascular, Renal & Metabolism at AstraZeneca.

Michael Buschle
More than 25 years of experience in basic research as well as biotech and pharma R&D. Experience at mid-size pharma and biotech companies including in- and out-licensing of assets as well as from C-level positions. Longstanding experience in investment consulting and financing and currently a consultant within the biotech industry for HBM Partners AG.

Yasir Al-Wakeel
Yasir is a seasoned executive, board member, and strategic advisor to biotech companies. He is currently the CEO of a genetic medicines company based in California and serves as an independent board member for Maxcyte. Yasir has had operational experience running finance and business development functions at both public and private biotech companies, and prior to that had senior roles in investment banking both as an equity analyst and in corporate finance.

Buloxibutid (C21) has disease modifying potential by driving lung repair

Buloxibutid is an oral, selective AT2R agonist with multiple beneficial effects on alveolar epithelial type 2 cells (AEC2)



Unprecedented clinical data with buloxibutid in IPF - Phase 2a AIR trial[1,2]



Note: Note: n=48 patients with 2-week FVC data. Observed values, no imputation. *p<0.05, **p<0.01, ***p<0.001; t-test versus expected untreated decline corresponding to -120 mL/24 weeks

References: [1] Noble et al. Eur Respir J. 2016 Jan; 47(1): 243–253, [2] Richeldi et al. Engl J Med 2014; 370:2071-2082

Advancing a diversified pipeline

Molecular Therapies

Compound	Indication	Preclinical	Phase 1	Phase 2	Phase 3	Comments	Rights
Buloxibutid (C21)	IPF					Phase 2b ongoing (NCT06588686)	Global ex-Japan rights; Japan: NIPPON SHINYAKU CO., LTD.
New ATRAGs	Multiple Indications					Preclinical studies	Fully-owned

Digital Therapies

Compound	Indication	Preclinical	Phase 1	Phase 2	Phase 3	Comments	Rights
Aimee™ DTx	PF[1] Anxiety					Pivotal study (NCT05330312) completed	Fully-owned

Strong preclinical evidence for buloxibutid (C21) in pulmonary fibrosis



Reference: Vicore data on file

Buloxibutid (C21) reduces fibrosis, collagen content and reverses vascular remodeling



Reference: Bruce et al. 2015, Rathinasabapathy et al. 2018, Tomling et al 2023

Vicore Presence at the ATS 2025 Congress

Buloxibutid (C21) ongoing global Phase 2b ASPIRE trial in IPF NCT06588686

- 52-week Phase 2b, randomized, double-blind, placebo-controlled, parallel-group clinical trial designed to assess the efficacy and safety of buloxibutid in IPF patients who are either not currently on treatment or receiving background nintedanib standard of care.
- Participants are randomized to receive one of two doses of buloxibutid (100 mg or 50 mg taken orally twice daily) or placebo. The primary endpoint is change from baseline in forced vital capacity (FVC). Secondary endpoints include safety, tolerability, and the proportion of patients with disease progression over the trial period.
- The trial will enroll 270 patients from over 90 sites across 14 countries, including the United States.
- Recruitment ongoing
- Check out our ASPIRE clinical trial booth at ATS (CT5 South Lobby)

ASPIRE

Oral and Poster Presentations

A Digital Psychological Therapy Improves Health-related Quality of Life in Pulmonary Fibrosis Patients Using Antifibrotic Treatment
- Mini Symposium A14: Advances in the Diagnosis and Management of ILD
- Date: Sunday May 18, 2025
- Presentation Time: 10:03 AM PT
- Location: Room 25, Hall E (North Building, Exhibition Level), Moscone Center
- Oral Presentation

ASPIRE Trial in Idiopathic Pulmonary Fibrosis: A Patient Experience-focused Phase 2b Randomized, Double-blind, Placebo-controlled, Multicenter Trial of the Novel Angiotensin II Type 2 Receptor Agonist Buloxibutid
- Thematic Poster Session A74: Fibrotic Lung Disease Revisited
- Date: Sunday May 18, 2025
- Presentation Time: 11:30 AM PT
- Location: Area G, Hall F (North Building, Exhibition Level), Moscone Center
- Poster Presentation

Buloxibutid Potently Inhibits Fibrosis Biomarkers in the Scar-in-a-Jar Primary Human Lung Fibroblast Assay
- Thematic Poster Session B75: Targeting Cellular Senescence, Immune Dysregulation, and Metabolism in Lung Injury and Fibrosis
- Date: Monday May 19, 2025
- Presentation Time: 11:30 AM PT
- Location: Area L, Hall F (North Building, Exhibition Level), Moscone Center
- Poster Presentation

The AIR Phase 2 Trial of the Angiotensin II Type 2 Receptor Agonist, Buloxibutid, in Individuals With Idiopathic Pulmonary Fibrosis: A Responder Analysis
- Mini Symposium D98: Tracing the Scar in Interstitial Lung Diseases
- Date: Wednesday May 21, 2025
- Presentation Time: 12:24 PM PT
- Location: Room 3006/3008 (West Building, Level 3), Moscone Center
- Oral Presentation



Thank you to patients and their caregivers for supporting our trials. We recognize your contribution to research.



RIS Respiratory Innovation Summit
ATS 2025 May 16-17 San Francisco

vicore pharma